Subject:
- Active Substance: Diroximel fumarate
- Name: Vumerity®
- Therapeutic area: Multiple sclerosis
- Pharmaceutical company: Biogen GmbH
Time table:
- Start: 01.01.2022
- Publication of assessment: 01.04.2022
- End of public hearing: 22.04.2022
- Final decision by G-BA: Temporarily suspended
Comparative therapy:
- Interferon β-1a or interferon β-1b or glatiramer acetate or dimethyl fumarate or teriflunomide or ocrelizumab, taking into account the drugs' approval